Safety and Efficacy of a Multi-branched Thoracoabdominal Stent Graft System for Thoracoabdominal Aortic Aneurysm.

Launched by LIFETECH SCIENTIFIC (SHENZHEN) CO., LTD. · Sep 14, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating a new type of medical device called a multi-branched thoracoabdominal stent graft system, which is designed to treat thoracoabdominal aortic aneurysms. An aortic aneurysm is a bulge in the aorta, the large artery that carries blood from the heart, and if it gets too big, it can be very dangerous. The trial aims to see how safe and effective this new stent graft system is for people who have been diagnosed with this condition.

To participate in the trial, individuals must be between 18 and 80 years old and have a thoracoabdominal aortic aneurysm that meets certain size criteria. They should also be able to understand the purpose of the trial and agree to take part in it. Participants can expect to be closely monitored throughout the study, and their health outcomes will be evaluated to determine how well the new device works. It's important to note that this trial is currently recruiting participants, and those interested should discuss it with their healthcare provider to see if they qualify.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. 18 years old ≤ age ≤ 80 years old;
• • 2. Diagnosed as thoracoabdominal aortic aneurysm (based on modified Crawford classification and 2019 European Guidelines for the Treatment of Aortic aneurysm) and should meet at least one of the following conditions;
• • 1. Maximum diameter of thoracoabdominal aortic aneurysm\>50mm;
• • 2. The diameter has increased by more than 5mm in recent 6 months or the by more than 10mm in recent 1 year;
• • 3. anatomical criteria
• • 1. The proximal anchoring region (aorta or implanted graft) was 17\~36 mm in diameter and ≥25 mm in length;
• • 2. Distal anchoring region (aorta or implanted graft): If the distal anchoring region is in the iliac artery, the anchoring region has a diameter range of 7\~25 mm and a length of ≥15 mm; If the distal anchoring area is in the abdominal aorta, the diameter of the anchoring area ranges from 12\~36mm and the length≥ 20mm;
• • 3. The diameter of the vessel anchoring area of the visceral branch ranges from 6\~13 mm and the length ≥15 mm;
• • 4. The diameter of renal artery anchoring area ranges from 4.5\~9mm, and the length ≥15 mm;
• • 5. Appropriate iliac, femoral and upper limb artery access;
• • 4. Patients who can understand the purpose of the trial, voluntarily participate and sign the informed consent, and are willing to complete the follow-up according to the requirements of the protocol;
• Exclusion Criteria:
• • 1. Hemodynamically unstable patients with ruptured thoracoabdominal aortic aneurysms;
• • 2. Thoracoabdominal aortic dissection;
• • 3. Mycotic or infectious thoracoabdominal aortic aneurysm;
• • 4. Patients whose systemic or local infection may increase the risk of intravascular graft infection;
• • 5. Superior mesenteric, celiac, or renal artery occlusion;
• • 6. Requiring simultaneous coverage and embolization of bilateral internal iliac arteries;
• • 7. Severe stenosis, calcification, or mural thrombus in the anchoring area of the stent tend to have difficulty in attachment of the stent-graft or affect the patency of the stent;
• • 8. A history of acute coronary syndrome within 6 months; Acute coronary syndrome is defined as an acute ischemic syndrome of the heart resulting from the rupture or erosion of unstable intracoronary atherosclerotic plaques followed by fresh thrombosis, including ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction, and unstable angina pectoris.
• • 9. Transient ischemic attack (TIA) or ischemic/haemorrhagic stroke within 3 months;
• • 10. Preoperative liver renal function abnormalities (ALT or AST ≥ 5 times the upper limit of normal value), or serum creatinine ≥ 150 μmol/L;
• • 11. Severe pulmonary insufficiency who cannot tolerate general anaesthesia;
• • 12. Severe coagulation dysfunction;
• • 13. Undergone major surgical or interventionic surgery within 30 days before surgery;
• • 14. A history of allergy to contrast agents, anticoagulants, antiplatelet drugs, stents, and conveyor materials (nitinol, polyester, PTFE, nylon);
• • 15. Connective tissue diseases such as systemic lupus erythematosus, Marfan's syndrome, Adam's syndrome, or Behcet's disease;
• • 16. takayasu arteritis;
• • 17. Serious vital organ dysfunction or other serious disease;
• • 18. Planning pregnancy, pregnancy, or breastfeeding;
• • 19. Patients who participated in other clinical trials and was not discontinued or withdrawn within the first 3 months of the screening period of this trial.
• • 20. Life expectancy less than 1 year;
• • 21. Patients who, in the judgment of the investigator, are not eligible for endotherapy.